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INTRODUCTION 
 
            Colorectal carcinoma is the third most common cancer in the 
world. Men have an edge over the women. Peak incidence is in the 
seventh decade. India has  a  lower incidence of colorectal carcinoma 
when compared to the western world. Though India has a low prevalence 
of about 87/10,000, there is a rapid increase in colorectal carcinoma cases 
which is attributed to the increase in life expectancy  and  changing life 
style. The various screening procedures such as colonoscopy, 
advancements in the radiological diagnosis have helped to detect the 
disease at early stages. 
          The rapid developments in the field of molecular genetics has 
helped us to understand the molecular biology of colorectal carcinoma 
thoroughly . The tumour suppressor genes eg TP53/ P53 and the 
oncogenes  eg Kras are involved in the normal cellular functions . Poor 
response to chemotherapy has been attributed to mutations involving the 
TP53 gene and KRAS  gene of the RAS family.More than half of the 
colorectal carcinoma  patients  exhibit  TP53 gene  mutation  KRAS  
mutation  is observed in about 40-50%  of colorectal carcinoma patients.  
Both these mutations occur as late events in the disease process. They  
cause  increased  tumour growth  and  prevent apoptosis.  
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             Tumour suppressor gene  TP53   regulates cell  cycle progression,  
DNA repair, cellular senescence and apoptosis. TP53 encodes P53 
Protein .Either loss of function in  TP53 gene or  mutation in   MDM2  
gene  may result in   increased degradation of  P53.  
                 With  loss of function of P53, DNA damage goes unrepaired,  
driver mutations accumulate in oncogenes and other cancer genes, cell 
marches blindly along a dangerous path leading to malignant 
transformation. Further clinical studies have shown that P53 protein is 
required for the response of colorectal  carcinoma to 5-Fluouracil based 
chemotherapy. Hence P53 mutation detection  could  identify colorectal 
carcinoma  patients who are  likely to benefit   from Standard 
Chemotherapy regime used for colorectal carcinoma patients. 
              Receptor tyrosin kinase     activation  stimulates RAS and two 
major  signaling arms   Mitogen activated protein kinase –MAPK 
pathway and the Phosphoinositidyl  3—Kinase –PI3K/AKT  pathway . 
The components of these  pathways are important in mediating cell 
growth. They are frequently involved in gain of function mutation in 
different types of cancer. The RAS genes family includes HRAS, KRAS 
and  NRAS. Among these KRAS is the commonly mutated gene. On 
activation KRAS protein is capable of turning off  the signaling pathways  
by  catalysing hydrolysis of GTP to GDP. This leads to continuous 
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activation of downstream  pathway. Mutated  KRAS protein have 
impaired intrinsic GTPase activity which renders the protein resistant to 
inactivation by regulatory GTPase activating protein. 
                In the era of molecular genetics it is mandatory to do genetic 
studies in malignant diseases. The pathologist role has been extended to 
include the genetic abnormality in the diagnosis of the disease and also to 
provide important information  to the surgeons and the oncologists for 
further management.  
                 Immunohistochemistry  is less time consuming, less expensive 
and an alternate method to identify genetic mutations.  
         Studies have  found  that  KRAS   mutation in  colorectal   
carcinoma   is associated with poor response to EGFR inhibitors-
Cetuximab and Panitumumab and refractory to Chemotherapy. Here 
again the aim of the present  study is to analyse clinical and 
histomorphological features of  colorectal carcinoma and to identify the 
occurrence of TP53,and KRAS mutation in colorectal carcinoma patients 
by immuno histochemical  studies and help to redefine  targetted  therapy 
(monoclonal antibodies) and  chemotherapy. 
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AIMS & OBJECTIVES 
 
Aim  :  
To determine the Expression of TP53/P53 and KRAS in Colorectal    
carcinoma in a Tertiary Health care Centre. 
Objectives: 
1. To establish the diagnosis of colorectal carcinoma by 
Histopathological Examination. 
2. To detect the Expression of P53and  KRAS proteins in Colorectal  
carcinoma by  Immuno Histochemical  studies. 
3. To establish the molecular signature of Colorectal Carcinomas in our     
centre.                                                              
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REVIEW OF LITERATURE 
 
         The colorectal carcinoma is the most common malignancy of the 
Gastro intestinal tract
 (1)
 and has a high morbidity and mortality. Studies 
have shown that the molecular and genetic alterations define the behavior 
and  the outcome of the colorectal carcinoma. Again the studies of 
colorectal carcinogenesis have shown that Kras and TP53  mutations
(2)
 
are late events and are  involved in the progression of Colorectal 
carcinoma.  Kras mutation
(3)
 is associated with recurrence of colorectal 
carcinoma, poor  outcome and resistance to EGFR  inhibitor  Cetuximab 
and Panitusumab
(4)  
TP53  mutation  is associated with poor outcome.  
Tumour suppressor genes such as  TP53 as well as  oncogenes like  
Kras  are   involved  in  the maintenance of normal functions of the cell
1
. 
The mutational activation of proto oncogenes  leads to increased and 
unregulated growth(1). The loss of the  tumour suppressor genes
1  
by 
mutations leads to the breakdown of a variety of cell functions  including  
DNA repair,  intercellular adhesion and recognition, cell cycle control 
and  multiple signaling pathways implicated in the cell regulation.  
Oncogenes are dominantly acting,
(5)
 Mutations of one allele is 
sufficient  to execute a transforming event. Though several oncogenes are 
implicated in the carcinogenesis and outcome of colorectal carcinoma 
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depends on molecular signature.. Kras  and BRAF are oncogenes that are 
more frequently mutated in colorectal carcinomas. Tumour suppressor 
genes are recessive in that both alleles  need to be inactivated before  they 
execute  their oncogenic effect. The most frequently  mutated  tumour 
suppressor gene is in colorectal carcinoma is TP53 and is a late event  and 
common in tumours that do not display CpG island  hypermethylation 
LARGE INTESTINE
(5) 
The large intestine extends from the distal end of the ileum to the 
anus measures a length of 150 cm, and consists of  caecum, appendix, 
colon, rectum and  anal canal. The large intestine begins in the right groin 
as the caecum with its appendix continues upwards   as the ascending 
colon and  makes through  the right flank into the  right  hypochondrium. 
Just below the liver bends to form the colonic/hepatic flexure and crosses 
the abdomen as transverse colon. Just below the spleen it bends 
downwards forming the left colonic flexure and continues as the 
descending colon through the left flank into the groin.  Enters the pelvic 
cavity as the rectum and  finally  terminates  as the anal canal. 
The  caecum the ascending colon and the transverse colon are 
supplied by  the branches of  the superior mesentric artery. The rest of the 
colon are supplied by the branches  of  the inferior mesentric artery. The 
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rectum is supplied by the rectal branches of the Inferior mesenteric artery 
, Internal iliac artery and the Internal pudendal artery. The lymph vessels 
of the caecum drain into the nodes that are along the ileocolic and  the 
right colic artery. Lymph vessels of the transverse colon drain to the 
nodes along the middle colic artery and those of the descending and the 
sigmoid colon drain to the nodes along  the left colic and the Sigmoid 
areries. The Lymph vessels of the rectum drain to the nodes that are along 
the rectal branches of the inferior mesenteric artery and the pudendal 
artery. 
The Nerve supply:
(5) 
The parasympathetic supply to the proximal colon is through the 
Vagus.  The distal colon and the rhectum are supplied by the sacral 
nerves. The sympathetic nerve supply is through the lower  spinal nerves.  
EMBRYOLOGY :    
The   caecum, the  appendix,  the ascending colon and a variable 
length of  the transverse colon  have  midgut origin. They derive their 
blood supply from the superior mesentric artery.  
           The descending colon, sigmoid colon, Rectum and  two third of 
the anal canal are derived from the hind gut .They are supplied by the 
inferior mesentric artery.  The distal part of the anal  canal originates 
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from the ectoderm, Whereas the cranial part arises from the endoderm the 
caudal part is derived from the ectoderm.  The cranial part derives the 
blood supply from the  superior rectal artery and the caudal receives from 
the inferior rectal artery. 
HISTOLOGY:    
     Large intestine mucosa is composed of  Epithelial tubules 
embedded in the connective tissue frame work of lamina propria and 
resting on the muscularis Mucosa. Epithelial component consists of 
straight perpendicular tubules or crypt which are parallel to one another. 
The crypts are  ensheathed  by smooth muscle cells or myofibroblasts. 
Four main cell types are represented within the crypts and the 
surface epithelium. First and numerous are the columnar cells. Other cells 
are the Mucin filled goblet cells, the Paneth cells with large sized 
supranuclear eosinophilic granules usually limited to the  right colon and  
the endocrine cell with small subnuclear eosinophlic granules present  
commonly in the rectum. The sub mucosa is composed of collagen and 
reticulin fibres ,blood vessels lymphatics, nerves along with small groups 
of ganglion cells beneath the muscularis  mucosa. Muscularis propria is 
made of circular muscle layer and longitudinal muscle layer.  Between   
the two layers lie the myentric plexus. The serosa is the thin sheet of 
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connective tissue containing blood vessels and  lymphatics  covered by 
the peritoneum. 
PHYSIOLOGY:  
      Essential function of the large intestine is to receive the fluid chime 
from the Small intestine extract water and prepare the the faeces for 
defaecation. The Large Intestine absorbs water and electrolytes whereas 
during the pathological conditions it can also secrete fluid.  The right 
colon alters the fluid chyme by absorbing fluid and electrolytes and 
fermenting the carbohydrates.  
        The transverse colon and the descending colon serve as organs of 
storage and propulsion. No absorption takes place in the sigmoid colon 
and the rectum. The ectum is the region of continence control.  
COLORECTAL CARCINOMA –AN OVER VIEW:   
       Malignant tumour of the epithelium of  either the colon or the 
rectum. Can occur anywhere in colon & rectum. Tumours which have 
invaded the muscularis mucosa and further invade the  Submucosa carry 
poor prognosis.  
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DIET AND LIFE STYLE:    
Incidence of Colorectal carcinoma is high in people consuming food rich 
in animal  fat. 
Common risk factors: 
Consumption of Alcohol  
 Smoking  
Consumption of  Meat, refined carbohydrates.  
Diet rich in fibre, vegetables and trace elements have a protective role. 
Patients suffering from Inflammatory Bowel Disease are at risk of 
developing Colorectal carcinoma. 
Modifying Factors: 
Nonsteroidal anti-inflammatory
(1)
 drugs have a role in the 
Chemoprevention of Adenocarcinomas. NSAIDS  block the synthesis of 
Prostaglandins which  have a role in the  proliferation of  the Colonic 
epithelium. 
ENVIRONMENTAL FACTORS:   
Various dietary hypotheses have been put forward  and the 
summation of the various factors are finally responsible for the 
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development of  a carcinogenic environment. Increased consumption of 
animal fat results in the increased production of bile acid. It is suggested 
that bacteria within the large intestine may act upon the bile acids
(6)
  
producing carcinogens. Many studies have given evidence that the bile 
acids act as tumour promoter.  
 Increased faecal bile acids concentration   either by dietary or 
surgical manipulations increase the incidence of  colorectal carcinomas in 
animal experiments. Studies have revealed that high intake of refined 
carbohydrate are associated with the development of adenomas in colon 
and rectum.  
There are  evidences to show that restricted calories inhibits the 
formation of colorectal tumours. Vegetables
(7)
 have protective influence 
by induction of  hydroxylase enzyme. This neutralizes the noxious agents 
present with in the gastrointestinal tract. Selenium
(8)
 deficiency also has 
been implicated in the increased incidence of right sided colonic cancer.  
ENDOGENOUS FACTORS:
 
Observations have shown that hormones may influence the 
Adenoma- Carcinoma sequence. Oestrogen 
(9)
  may have an indirect 
effect on the bile acids and lipids. Individuals with acromegaly  have 
increased risk of developing  colorectal carcinoma.  
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GENETIC FACTORS: 
Cancer is a genetic disease that is brought by the stepwise 
development of multiple sequential mutations. Though mutations eg: 
APC gene mutation are inherited many are acquired somatic genetic 
changes.  Inherited mutated  Adenomatous poliposis coli gene /APC
(1)
  a 
tumour suppressor gene is most often implicated in the Familial 
adenomatous  poliposis coli. Again APC gene  is involved in the 
histogenesis of  majority of the sporadic Colorectal carcinomas.  
Similarly, inherited mutated DNA mismatch repair gene
(5)
 
(microsatelite instability)  is  involved in the genesis of about fifteen 
percent of autosomal dominant hereditary nonpolyposis colorectal 
carcinomaand these tumours are  not characterized by the presence of 
either the mutated APC gene or the Cpg island hypermethylation  and 
these tumours are more common in  the proximal colon.
(10) 
  Individuals with germ line mutations are expected to be young 
and again have  family members  affected with colorectal carcinoma. It is 
interesting to note that  Hypermethylation of CpG island is found in a 
subset of colorectal carcinoma patients without mutations in DNA 
mismatch repair and are also  associated without mutation of genes of 
Microsatelite instability and BRAF mutations are common in these 
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patients but without Kras and TP53 mutations and also to state that in 
another group  of colorectal cancers CpG island Methlation is found 
without Microsatelite instability and these cases harbor Kras mutations 
with out BRAF and TP53 mutations.  The other polyposis syndromes that 
have increased risk of developing Colorectal  Carcinomas are The 
Juvenile polyposis,
(11)
 The Hyperplastic polyposis
(12), 
The mixed 
polyposis syndromes
(13). 
The gene linked in the colorectal carcinoma in which few number 
of Adenoma and serrated polyps do occur is the loci on the long arm of 
chromosome 15. The Genetic  factors need not act at the somatic level in 
the tumour genome  They could   influence  the  intermediary  mechanism 
involved in the detoxification  of potential  mutagens or either aid in the 
synthesis or promotion of the potential carcinogens. Studies have 
identified that  Glutathion S- transferase  null genotype
(14)
 is associated 
with increased risk of colorectal carcinoma. 
This is inferred from the fact that glutathione S- transferase 
detoxify carcinogens that includes epoxides of polycyclic aromatic 
hydrocarbons. Well known fact is that leafy vegetables are protective 
against colorecatal carcinoma which is mediated by folate there by 
influencing the availability of Methyl group.    
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Cytochromes CYP1A1  and CYP2D6  are involved in the 
conversion of polycyclic aromatic hydrocarbons. Studies have shown  
mutant genotype  of CYP1A1
(15)
 associated with colorectal carcinoma.  
HISTORICAL  HIGHLIGHTS: 
It was only after 1960 Colorectal  carcinomas  were  recognized as 
a distinct   malignancy of  the GIT.  Incidence  rates  of colorectal 
carcinomas is on the raise  since 1970.  Incidence  declined between 1980 
and 1990. There was a short period of stabilization. In between  1998  and  
2005,  incidence  again  declined  which was   2.8%  on average  per  year  
for men and 2.2%  per  year in woman.  Mortality following colorectal 
carcinomas  has  declined  over  the last  20 years. The raise in the 
incidence as well as the reduction in the mortality rate are largely due to 
the screening processes, advanced techniques  in the diagnosis and the 
management. 
EPIDEMIOLOGY : 
   Colorectal  carcinomas usually occur between  60  to  70  years
(16)
  
of  age.  20%  colorectal carcinomas are encountered before  40  years.  
These have  an  inherited predisposition.  Males have an edge over the  
females. Prevalence is  more  in the developed  countries  than  the  
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developing countries . In India there is increasing incidence of colorectal 
carcinomas ,probably due to altered food habits and life style.  
ETIOLOGICAL FACTORS : 
RISK  FACTORS  -NON MODIFYABLE  
1. Age:   Incidence increases after the age of  50 . 
2.  History of Adenomas: 
      The neoplastic polyps namely  Villous Adenomas  and Tubular 
adenomas  are  precursors  of colorectal  cancer. Individuals with  
adenomas are more prone to develop colorectal carcinoma. Most of the  
colorectal  cancers  develop from pre existing  adenomas.  However,  a  
latency  period  of  5  to  10  years  is needed  for  the transformation  to  
malignancy.  
3. Inflammatory  Bowel  diseases:  
a). Ulcerative  colitis.
(17)
  b).  Crohn’s   disease(18)   
The estimated  risk in developing colorectal carcinomas in Inflammatory 
bowel diseases  is about 4 to 20 fold.  
4.Juvenile polyposis. 
5. Family history of Colorectal cancer or adenomatous polyp: 
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Colorectal carcinoma develops in 20% of people with family history of 
either colorectal cancer or adenomatous polyps. 
GENETIC FACTORS: 
Colorectal carcinoma is associated  with the following inherited 
conditions. 
FAMILIAL ADENOMATOUS POLYPOSIS: 
Mutation in tumour suppressor gene APC gene located on chromosome 
5q21 causes  Familial  Adenomatous polyposis (FAP),  accounts for less 
than 1% of colorectal carcinomas. 
 Hereditary Non-polyposis colorectal cancer (Lynch syndrome) 
Here Mutations in MLH1 and MSH2 genes lead to DNA Mismatch repair 
and account for around 2 % of colorectal carcinomas. The Mutations 
cause Microsatellite instability and tumors arise in the proximal colon 
with mucinous features . 
PATHOGENESIS 
The combination of various molecular events   lead to the genesis of 
colorectal carcinoma. It is a heterogenous combination which includes the 
Genetic and the Epigenetic abnormalities
(1)
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The two commonest Genetic Pathways involved are the 
1. Adenomatous poliposis coli / Beta catenin Pathway(1)  Associated 
with Adenoma – Carcinoma sequence  
2. Micro Satellite instability pathway associated with the defects in 
the DNA mismatch repair and the subsequent multiple mutations 
accumulating in the microsatellite regions  of the Genome. 
       Both of the above pathways involve many sequential 
mutations which occur in different genes.  
 
Classic Adenoma – Carcinoma Sequence(1) 
 Classic adenoma –carcinoma sequence accounts for about 80%(1) 
of the sporadic colonic malignancies. It naturally includes mutation in the 
Adenomatous  polyposis  coli and occurs early  in the process of  
neoplasia. It requires both the alleles of the Adenomatous Polyposis coli 
gene to be  inactivated. Inactivation of the gene may be either by 
epigenetic event or genetic mutation.  
Beta catenin
(1)
is a component of the WNT signaling pathway and 
the key negative regulator of the  Beta catenin is the Adenomatous 
polyposis coli gene. The protein encoded by the Adenomatous polyposis 
coli promotes the degradation of Beta catenin.  Loss of function of 
Adenomatous polyposis coli by mutation results in the accumulation of 
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Beta catenin. Beta catenin gets located to the nucleus, combines with the 
TCF DNA binding factor
(1)
 and  then occurs the activation of 
transcription of the genes. The transcription of genes include Myc and 
Cyclin D1 genes that promote cell proliferation. It has been demonstrated 
that colonic cancers which do not harbour Adenomatous Polyposis Coli  
may  harbor  mutations  in  the  Beta catenin.   
This helps the Beta Catenin to avoid the degradation by the 
Adenomatous polyposis coli   protein  and  paves for  cell  proliferation.  
Additional mutations such as KRAS mutations do occur  during the 
progression of the neoplasia which prevent apoptosis and promote cell 
proliferation and conversion of the Adenoma Lesion to carcinoma.  Few 
other mutations are the mutations of the tumour suppressor gene SMAD2 
and SMAD4  which  are  involved  in  the  Transforming growth  factor  
signaling. 
Normally the Transforming growth factor  inhibits the cell cycle 
progression. Hence mutation in Transforming growth factor will 
allowunrestrained growth of the cell. Like wise, Tumour suppressor gene 
TP53 is mutated in 70 – to 80% of colonic cancers.  
Loss of function in tumour suppressor genes including TP53 is 
most often due to chromosomal deletions,
(19)
 supporting the fact that 
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chromosomal instability is the major cause of Adenomatous Polyposis 
coli – Beta Catenin pathway. As an alternate mechanism the tumour 
suppressor genes may be silenced by methylation of the CPG island
(20)
 or 
the CPG rich Zone 5’  region of some genes. These regions happen to be 
zones of promoter and transcription starting sites.  As the neoplasia 
advances expression of the Telomerase enzyme also increases. 
DNA mismatch repair Deficiency:
(1) 
Microsatellites are regular repeats of one to six nucleotides and  is 
observed all through out the genome. The length of the microsatellite 
zones remain constant in normal individuals. However this  gets disturbed  
with either  an increase or decrease in the length  of the micro satellite in 
the tumour cells. Mutations  in the micro satellite repeat zone is identified 
as Micro satellite instability  and is the cause in DNA Mismatch repair 
deficiency. The tumours are referred  as Microsatellite instability High 
tumours (MSI-H). Studies demonstrate a few of microsatellite sequences 
located in the promoter or coding regions of the genes  to involve in the 
regulation of the cell growth. These encode the type II Transforming 
Growth  factor Beta receptor and the pro apoptotic protein BAX. 
Transforming Growth factor Beta naturally inhibit the proliferation of the 
colonic epithelium. Hence mutation in type II Transforming growth factor 
Beta receptor will promote uncontrolled cell proliferation.  
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Further loss of function of BAX protein will result in the survival of the 
genetically unstable clones.  
A sub group of Microsatellite instability colonic cancers, instead of 
mutations in the DNA mismatch repair enzymes may demonstrate CPG 
island  hypermethylation  phenotype. These tumours demonstrate 
hypermethylation of MLH1 promoter regions. This reduces the 
expression of MLHI and its repair function. Mutations in BRAF 
oncogene is common in these tumours  whereas these do not harbor either  
KRAS  or TP53 mutations. The feature of this pathway’s carcinogenesis 
mechanism is the combination of Microsatellite instability, BRAF 
mutation  and  hypermethylation  of specific targets such as MLHI. 
Another sub group of the colonic cancers demonstrate increased 
methylation of CPG island with no Microsatellite instability. These 
tumous harbor only KRAS mutations with no TP53 or  BRAF Mutations. 
TP53 mutations are commonly found in tumours which do not 
demonstrate CPG island methylation Phenotype. Studies have shown that 
tumours with Microsatellite instability have mucinous differentiation 
along with lymphocytic infiltration  around the tumour. Another striking 
feature is the occurance of these tumours along with the tumours with 
CPG island hyper methylation phenotype in the right colon. 
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Histogenesis of colorectal cancer. 
The sequence of dysplasia in the form of adenoma transforming to 
carcinoma is considered to be the morphological counter part of the 
multisteps involved in carcinogenesis of colorectal malignancy.In APC 
related tumours and othertumpurs related to tumour suppressor genes 
individuals inheriting one allele mutation are at increased risk of 
developing colorectal neoplasia if they develop mutation of other allele 
later in life. Following changes such as mutation in KRAS genes, 
mutations in SMAD2 and SMAD 4 or  inactivation of tumour suppressor 
genes may lead to the emergence of carcinoma.  
      Here again the accumulation of many mutations are critical in the 
genesis of colorectal carcinoma. Dysplasia also occurs in other clinical 
conditions which are associated with an increased risk of developing 
colorectal cancer.  
They are , Ulcerative colitis, Crohn’s  disease  
In patients with juvenile polyposis &  Radiation associated
(5) 
            Studies have identified individuals presenting with multiple 
tumours and these tumours  happen to be synchronous.
(5)
 Few patients 
presenting with either solitary Adenoma or Carcinoma may subsequently 
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develop  additional tumours. Individuals presenting with Colorectal 
cancer and synchronous Adenomas show better survival rates.  
The role of  Kras protein & Tumour suppressor gene: 
K-RAS & TP53/P53: 
            The biology of cancer includes Tumour cell proliferation which  is  
independent of growth signals, usually consequent  to oncogene 
stimulation.  
Tumour cells are insensitive to Tumour suppressor gene’s 
inhibitory signals. Alteration occurs  in cell metabolism such that tumours 
adapt to aerobic glycolysis and cancer cells evade apoptosis. There is 
unrestricted replicative capacity of the tumour cells and sustained 
angiogenesis. There is invasion into adjacent structures and spread to 
other anatomical locations.  
Cancer cell’s have the  capacity to evade the individual’s immune 
response. 
ONCOGENE
(21) 
 Oncogenes  are genes which promote autonomous growth of the 
cell. 
 Proto-oncogenes are unmutated forms of the oncogenes. 
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 Proto-oncogenes when they undergo mutation become oncogenes.  
 Oncogenes encode protein molecules called oncoproteins and these 
have the ability to promote autonomous cell growth. 
 Further the oncoproteins have the potency to dysregulate the 
internal regulatory system of the cell. Consequent of this, the 
oncoproteins become independent of their action and cause excess 
proliferation of the tumour cells. 
Growth factor Signaling pathways
(1)
                                                                                                                                                                                                                                      
 The function of the signaling pathways is to regulate the behavior 
of the individual cells. 
 Common signaling pathways are  
 Receptor tyrosine kinase pathway  
 WNT pathway 
 Notch receptor pathway  etc. 
 Abberations occurring in the transduction of signals are implicated 
in the development and progression of cancer and this occurs as a 
result of mutation in the components of these pathways.The 
mutated components are the oncoproteins. 
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 The Receptor tyrosine kinase pathway
(22)
 is the most commonly 
mutated signaling pathway. Oncoproteins accelerate the process of 
proliferation whereas the tumour suppressors apply brakes to either slow 
down or curtail the process. It is well known that proto oncogenes  play 
multiple roles and all these participate at some level in the process of 
signaling pathways.  
        They encode oncoproteins which may act as growth receptors, 
Growth factor receptor, transcription factors, signal transducers and 
components of the cell cycle. These oncoproteins act like their 
counterparts but the significant feature is that they are constitutively 
active components and act independently. 
The growth factor signaling pathway in cancer: 
             RAS proteins  belong to the family of the membrane associated  
small G
(23)
 proteins. These proteins bind to the Guanidine diphosphate 
and Guanidine  triphosphate. During excited state of signal transmission 
these are bound to the Guanidine triphosphate whereas during the 
quiescent state these are attached to Guanidine diphosphate. The 
stimulation of tyrosine kinase receptor by the growth factors results in the 
exchange of Guanidine diphosphate for Guanidine `triphosphate. 
Subsequently there is generation of active RAS.   
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          RAS in turn activates the two arms of the Tyrosine kinase receptor 
pathway, the Mitogen activated protein kinase
(24)
  and 
Phosphatidylinositol 3- kinase/ AKT-Protein kinase
(25)
 B. These two 
downstream kinases phosphorylate numerous cytoplasmic effectors and 
many transcription factors. Transcription factors activate the genes which 
aid in the accelerated growth of the cell. Activation of the RAS molecule 
is  transient. RAS possess innate GTPase enyme
(26)
  activity which is  
accelerated by GTPase activating proteins which in turn curtail the 
uncontrolled activity of RAS.
 
RAS PROTEIN: 
          Studies have identified several distinct point mutations in the RAS 
protein which markedly  reduce the GTpase activity of the RAS protein 
.This allows the RAS protein to be entrapped in the Guanidine 
triphosphate bound form. As a result the cells receive continuous pro -
growth signals allowing the cells to grow in excess. Gain of function 
mutation or loss of function in Guanidine Diphosphate  result  in tumour  
cell proliferation. 
RAS MUTATIONS: 
     The RAS genes family includes  
 KRAS 
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 HRAS & 
 NRAS 
        The commonest abnormality involving the proto-oncogenes in 
human is the point mutations among the RAS family genes. KRAS
(27)
 
mutation is the commonest among the RAS proteins  mutations.  15% to 
20% 0f all cancers express mutations in the RAS proteins. 
 Some of the malignancies express high frequency of KRAS 
mutation. 
 They are,   
 90% in Pancreatic Adenocarcinoma &Cholangiocarcinoma. 
 50 % in Colon, Endometrial & Thyroid malignancies.  
 30 % in Myelogenous Leukaemia  & Lung Adenocarcinoma. 
 Although RAS point mutations are not prevalent in all 
malignancies it is found in almost all at  low frequency. 
 Regarding Adenocacinoma colon KRAS mutation occurs as a late 
event. 
 The observations from studies on colonic adenomas show  that 
very fewer than 10% of adenomas of size less than 1cm present 
with KRAS mutation  whereas they are found in more than 50% of 
adenomas of size greater than 1cm. 
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 Various studies have shown that colonic adenocarcinomas 
associated with KRAS mutation  are poor responders to Epithelial 
growth factor inhibitors ie  Cetuximab 
(28)
 and Panitumumab. 
 KRAS mutations are indicators of survival(29)  / poor prognosis. 
 Colorectal carcinomas associated with wild type  (30) /normal K-Ras 
show good response to Chemotherapy and  Monoclonal antibody 
therapy.  
TUMOUR SUPRESSOR GENES:  
 Another hallmark of carcinogenesis is the insensitive response of 
the tumour cells to growth inhibitory signals. The function of the tumour 
suppressor gene is to control cell proliferation. Hence any failure on the 
part of the tumour suppressor gene will lead to excess proliferation or 
rather failure of growth inhibition. Tumour suppressor genes execute their 
function through their protein products. These proteins act as 
transcription factors, signal transduction proteins,  cell cycle inhibitors, 
and  cell surface receptors. 
The tumour suppressor genes cause growth inhibition by 
promoting apoptosis, involving in cell differentiation. 
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TP53 gene through it’s protein P53 
 Tp53 gene reegulate the cell cycle development and also repairs 
the  defective DNA.Regulates cell senescence and Prods the cell to 
Apoptosis. TP53 gene is the most commonly mutated gene in 
malignancies. 
TP 53 mutation is located on chromosome 17p13.1 and these 
mutations are found in more than  50% of malignancies and in more than 
50% of  colorectal carcinomas. Loss of function  in p53 occurs as a late 
event in the adenoma –Carcinoma progression in about 60% of the 
colorectal cancers.  
Mutations of P53 can augument the migration of tumour cells and 
accelerate tumour invasion.
(31)
 Metastasis and invasion occurs by 
Epithelial –mesenchymal transiton, loss of cell to cell adhesion, increased 
cell motility. 
Inhibition of TP53 results in stimulation of TGF beta induced 
metastasis
(32)
. Invasion is accelerated through Integrin recycling 
pathway.
(33)
 P53 in  conjunction with HRAS activates the expression of 
Interleukins and Chemokines promotes Angiogenesis. Mutations 
involving p53 reduce the cancer cell sensitivity for many 
chemotherapeutic drugs example 5Fluorouracil.
(34) 
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Aminoacid loss causing mutation are associated with poor survival. 
Similar to K-Ras wild type TP53 wild type show better survival. 
P 53 expression is high in well differentiated colorectal carcinoma, 
little   less in the moderately differentiated carcinoma  and further less in 
poorly differentiated carcinoma.
(35)
 
EARLY COLORECTAL CARCINOMA
(36) 
The concept of early cancer defines the neoplasm which are 
confined with in the mucosa, have not invaded the muscularis mucosa 
and crossed into the submucosa. Further have no potential for lymph node 
deposits. These tumours are curable.  
MALIGNANT ADENOMA & POLYPOID CARCINOMA
(1, 37) 
This  is  a spectrum  which extends  from an adenoma with a 
microscopic  focus  of  malignancy  to polypoid  growth with no 
adenomatous focus. 
Focal Carcinoma in large Sessile Adenoma: 
Early cancer is diagnosed when the excised sessile growth is 
examined with care.  Mobile small ulcerative malignancies of the rectum 
show excellent results.  
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MACROSCOPIC APPEARANCE OF THE LARGE BOWEL 
CANCERS 
       Almost 40% of large Bowel malignancies involve the Rectum  and 
the Recto sigmoid region. 25% involve the sigmoid colon. Of the rest of 
the large bowel tumours  the ascending colon has more predilection. Of  
late there is a rise in the incidence of malignancy involving the right 
colon.
(38)
 Most of the tumours of the large bowel are ulcerating growths 
may involve the circumference of the bowel and cause stenosis. Few may 
be annular growth involving the entire circumference. These are called 
the string carcinoma. String carcinomas occur mostly in the transverse 
and descending colon. Exophytic growths are less common  and these are 
relatively of low grade. Few of the tumours may exhibit a  papillary 
configuration.  
Around 10% of the growth on cut surface show mucoid  
appearance. Most malignant growths of the large bowel are relatively 
small and circumscribed and they rarely extend   into the submucosa or 
muscular coat early stages. 
MICROSCOPIC APPEARANCE: 
Largely the large bowel cancers are adenocarcinomas, showing               
easily discerned Tubular differentiation. Majority of the tumours reveal a 
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circumscribed infiltrative margin.  20-25% show diffuse infiltration into 
smooth muscle and fat. About 20% show highly irregular or poorly 
differentiated tubules.Yet  another 20% tumours are well differentiated. 
10% of the tumour account for mucinous adenocarcinoma with 50% of 
areas occupied by mucin. Mucinous carcinomas are commonly associated 
with hereditary non poliposis coli cancer. Mucinous carcinomas 
occurring in the rectum show poor prognosis.
(39)
 However mucinous 
tumours occurring in the proximal colon have a favourable prognosis.
(40)
 
They show high levels of DNA MicroSatellite instability with no TP53 
mutation.  
       Well differentiated tumours are lined by Tall columnar cells. The 
lining cells become cuboidal or polygonal with decreasing degrees of 
differentionwith evidence of abundant mitoses.   
          They show abundant mitoses, along with cellular and nuclear 
debris and may exhibit desmoplasia, necrosis and hyalinization. The other 
cells less commonly associated are paneth cell, neuroendocrine cell, 
melonocytes , sqamous cells and Trophoblasts. 
Histological Classification of Colorectal Carcinoma : 
 Adenocarcinoma 
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 Mucinous Adenocarcinoma 
 Signet ring cell carcinoma 
 Medullary Carcinoma 
 Adeno Squamous Carcinoma 
 Squamous Cell Carcinoma 
 Small Cell (Neuro enclocrine) Carcinoma  
 Undiffrentiated Carcinoma 
 Mixed Carcinoid – Adenocarinoma 
ADENOCARCINOMA USUAL TYPE: 
Many of the adenocarcinomas are moderately well differentiated 
glands, they are medium to large sized and may show moderate 
variability in the size of the glands and configuration. Stroma is of 
moderate amount.  
Well differentiated tumours show tall columnar cells lining the 
epithelium. They become cuboidal to polygonal with decreasing 
differentiation. They show abundant mitoses. Lumen of the glands are 
filled with mucus and debris. They may be associated with Papillary 
component. Prominent desmoplasia can be seen along with tumour 
necrosis and hyalinization. Variable amount of others cells such as paneth 
cells squamous cells and melanocytes are also found. 
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COLORECTAL CARCINOMAS SUB TYPES: 
Mucinous Tumours  
More than 50% are mucinous tumours. they occur in the young and 
usually present with advanced stage. Molecular event – DNA mismatch 
repair – Micro Satellite instability High Tumour. TP53 is less frequently 
positive. Mucinous tumous are soft gelatinous on cut surface and show 
little fibrous tissue on microscopy. 
They show abundant large glands embedded in pools of mucin 
with infiltrative margins, prognosis tend to be poor, invade the adjacent 
viscera  frequently with implants to the peritoneum.They  also 
metastasize  to the lymph  node beyond the pericolic region very often. 
Signet Ring cell Adenocarcinoma 
Signet ring cell carcinomas are composed of at least 50% of signet 
ring cells. It  comprises 0.5 to 1% of all colorectal carcinomas more 
young men are affected and is  associated with ulcerative colitis. It occurs 
equally in both the right and the left colon. It usually present as ulcerative 
growth with infiltrative appearances. Linitis plastic pattern of growth is 
observed in about 20% of the signet ring cell carcinomas. Microscopy 
shows mucous vacuoles pushing the nucleus to the periphery of the 
cytoplasm. 
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Few of the cells show centrally placed nuclei These tumours also 
present at an advanced stage. Penetration of the muscularis propria with 
peritoneal implants are very common in this type. Distant metastases are 
very common at the time of diagnosis.  
UNDIFERRRENTIATED CARCINOMA: 
These tumours show evidence of epithelial differentiation with no 
gland formation. They  present as bulk mass with soft consistency. 
Microscopy : 
Undifferentiatd carcinoma has high cellularity lack desmoplasia, 
and show extensive necrosis and cells are arranged in sheets cords or 
trabecular patterns. Tumours show uniform to marked nuclear variability. 
The presence of undifferentiated component raises the probability of the 
tumour bearing DNA mismatch repair deficiency. It may also be 
associated with lymphocyte infiltration. 
Medullary Carcinoma  
Medullary carcinoma is more  common in women . It occurs in 
caecum and proximal colon These tumours are composed of polygonal 
cells arranged in sheets with vesicular nucler and prominent nucleoli with 
abundant cytoplasm, associated with lymphocytic infiltration. 
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KRAS and TP53 expression are less likely in these carcinomas
(39)
 
and more likely to bear DNA  mismatch defects. 
 Differentiation from the undifferentiated and other non glandular 
carcinoma is crucial as this carcinoma has  a  favourable out come. 
Squamous cell carcinoma. 
Squamous cell carcinomas are very rare.It probably arise from the 
pluripotent stem cells. It can arise from foci of squamous meteplasia due 
to mucosal irritation.They are usually present in an adavanced stage.It  is  
pathologically similar to squamous carcinomas of other organs. It is 
necessary to exclude metastases from other sites.  
SARCOMATOID CARCINOMA: 
Sarcomatoid carcinomas  are extremely rare. More common in 
elderly and are  often bulky and fleshy tumours  with extensive 
haemorrhage. Microscopically show biphasic pattern of growth with both 
mesenchymal and epithelial combination. spindle cell component are 
either totally undifferentiated or show smooth muscle, cartilaguous or 
ossceous differentiation. Immuno histochemistry show keretin and 
epithelial membrane antigen positivity with focal positivity for S100 and 
myoglobin.  
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         Both the sarcomatoid and epithelial component share TP53 
mutations. They are fast growing and very aggressive.  
Adenosquamous Carcinoma : 
Adenocarcinoma is an extremely rare carcinoma. Frequent 
association of parathyroid hormone and paraneoplastic hypercaleaemia 
related protein have beern reported in primary colorectal adenosquamous 
carcinoma. It has also been identified in indviduals with ulcerative colitis. 
These carcinomas show both malignant squamous and glandular 
components. Over all survival rates are comparable to the staged 
adenocarcinomas. 
Poorly Differentiated Neuro Endocrine Carcinoma 
Small cell neuroendocrine and less common the large cell poorly 
differentiated neuroendocrine carcinomas may occur as primary 
colorectal carcinomas anywhere in the rectum and colon.  
It commonly occurs in the younger age. It usually arises from an 
adenoma.  Immunohistochemistry show positivity for  synaptophysin and 
chromogranin 
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Mixed glandular neuro endocrine composite carcinoma. 
Mixed glandular neuro endocrine composite carcinomas show dual 
differentiation of glandular as well as neuroendocrine features.It is a 
spectrum with one end showing evidence of endocrine cells and the other 
end showing adenocarcinoma. At the other end some  carcinoid 
tumoursmay   contain mucinous tumour cells.  
Diffuse carcinoma: 
Occasionally adenocarcinomas may present with a diffuse growth 
pattern and  show moderate differentiation.  Prognosis is extremely 
worse. 
Villous Adenocarcinoma: 
Villous adenocarcinoma type of adenocarcinoma is composed of 
more than 50% of villous architecture.  Many show severe atypia. 
Microscopy show epithelial islands in desmoplastic stroma. 
Special Studies: 
Studies show that as far as 30% of patients who have colorectal 
carcinoma confined to bowel at the time of surgery and Histopathological 
evaluation develop distant metastases later.  Subjection of sentinel 
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lymphnode to histopathological  examination and immune histochemistry 
is one method to identify individuals prone to develop distant metastases. 
Immuno Phenotype: 
Immunohistochemical studies are required to characterize the sub 
types. To differentiate primary carcinoma from metastatic carcinoma. 
Carcino embryonic antigen(CEA) though positive in most colorectal 
carcinoma, many non colonic carcinomas also show positivity for CEA.  
CK7 and CKZ20  
Though widely used are not diagnostic  
Villin Protein  
Though positive in colorectal carcinoma other carcinomas such as 
Lung Cancer are also positive.  
Of late CDX2 transcription factor has been used as a marker of 
intestinal differentiation. In non neoplastic elements it is expressed only 
by the epithelium lining the crypts.  Where as 90% of colorectal 
carcinomas express CDX2 factor. Few exception which do not express 
CDX2 are Medullary Carcinoma, DNA mismatch repair deficiency 
carcinomas. Important role of CDX2 is that loss of expression seen in the 
more aggressive tumours and in more advancing carcinomas.  
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Grading of Colorectal Carcinoma: 
Grading is restricted to adenocarcinoma of usual type. Grading is 
based on the  proportion of the tumour growth composed of well 
differentiated glands in relation to the display of solid sheets of tumour 
cells.  
Grade I well differentiated Adenocarcinoma. 
Tumour composed of well differentiated glands comprising more 
than  75% Tumour cells do not exhibit high grade nuclear features. They 
are designated as low grade. 
Grade II Moderately differentiated Adenocarcinoma  
The tumours are composed of 50 – 75% of glands - Low grade. 
Grade III - poorly differentiated Adenocarcinoma. 
Well differentiated glands comprise less than 50% - High grade. 
Grade IV Undifferentiated Adenocarcinoma. 
Comprise less than 5% of glands or show almost no glands - High grade. 
 Signet Ring Cell Carcinoma 
 Mucinous Carcinoma 
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 Small cell Carcinoma are considered as poorly differentiated 
carcinomas. 
CLINICAL FEATURES: 
Colorectal carcinomas may  either present with symptoms or are  
asymptomatic. Common  symptoms involving the Right colon are 
weakness and fatigue due  to  anaemia. Symptoms related to the 
carcinomas of left colon are occult bleeding, change in the bowel habits 
or discomfort in the lower quadrant of the left side of the abdomen. 
DIAGNOSTIC PROCEDURE: 
Imaging: 
The incidence of Colorectal carcinomaincidence has increased over 
past few decades largely due to the screening programmes, utilization of 
CT abdomen particularly in asymptomatic individuals. CT is sensitive 
and is better than conventional barium enema in detecting tumours of 
colon and rectum. Abdomen CT, MRI imaging and transrectal 
ultrosonography help in defining the  depth  of  the tumour and the 
margins of the tumour  and also help in the  detection of the regional and 
distant metastases.The other imaging studies used in addition are  
scintigraphy  and Positron  Emission Tomography. 
41 
 
TISSUE SAMPLING PROCEDURE : 
         Colonoscopic biopsy and sigmoidoscopic biopsy are the definite 
methods in establishing diagnosis of colon and rectal tumours to define 
further management. 
Common Indications of colonoscopy 
1. To screen high risk individuals supposed to develop Colorectal 
carcinoma. 
2. To evaluate and resect Adenomatous polyps. 
3.  Current or previous bowel resection for colon cancer 
4. In individual  with Family history of cancer 
5. In the Management of inflammatory bowel diseases. 
6. Subsequent to bleeding per rectum to identify the cause.  
7. Decompression of colon 
IMMUNOHISTOCHEMISTRY: 
 As elsewhere Immunohistochemistry is a supportive  technique 
which is commonly used in the  diagnosis of  colorectal tumours. 
Immunohistochemistry has largely replaced histochemical studies of  
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mucin. Electron microscopy helps in identifying early neoplastic changes 
in tumours of  colon and rectum. 
Markers in colorectal carcinoma 
The panel of Immunohistochemical markers used in colorectal 
carcinomas are 
1. MUC1 and MUC3 
2. P53 
3.  Cytokeratin  20  
4. Carcino embryonic antigen 
5. Her2 neu – Epidermal growth factor 
6. CDX2 
7. TAG-72-Tumour associated glycoprotein 
8. Cathepsin 
9. Villin 
10. HCG.          
11. PLAP- Placental Alkaline Phosphatase   
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Mucins are glycoproteins expressed in  many epithelial cells  are 
also expressed  in their malignant counterparts. The mucin  expression  is  
a prognostic indicator ,and also  has a role  in cancer therapyThe different  
mucins  are MUC1, MUC2, MUC3, MUC4, MUC AC and MUC6. 
MUC-1 and MUC3. 
MUC1and MUC3 are very commonly expressed in colorectal 
carcinomas of the  right colon.  
MUC2
(42)
 is the  mostly  commonly  expressed in mucinous 
carcinomas.  
MUC13 is more often  expressed in poorly differentiated colorectal 
carcinomas. Mucin  expression is encountered in other tumours also such 
as breast carcinoma, pancreatic and gastric carcinoma. 
MUC5AC commonly expressed in pancreato  biliary  tumours are 
not expressed in Colorectal carcinomas. 
CYTOKERATIN 20: 
           Cytokeratin 20 is   found in the  mature enterocytes and goblet 
cells and  is found  specifically in the mucosa of the stomach and the 
intestine.  KRT20 encodes the cytokeratin protein.  Invariably Colorectal 
adenocarcinomas express  cytokeratin 20.
 
CK 20 is expressed in 
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transitional cell carcinomas and in Merkel cell carcinoma. Cytokeratin 20 
expression is common in adenocarcinomas of  colorectum, lung ovary 
and prostate. Whereas cytokeratin -7 is not expressed in colorectal 
carcinomas and  thus helps to differentiate.
  
CARCINOEMBRYONIC ANTIGEN : 
(43) 
Carcino embryonic antigen is commonly found in developing 
foetus and expressed in many tumours such as adenocarcinomas of colon 
and rectum, pancreas, breast, stomach, ovarian cancer and in few thyroid 
cancers. Few benign conditions such as pancreatitis, cirrhosis infection 
and  inflammatory bowel diseases do express  CEA. In response to cancer 
therapy
(41)
  levels tend to fall  thus guide in the management.  
HER 2 NEU:  
Human epidermal growth  factor receptors also called ERBB2 
(Erb-b2 receptor tyrosine kinase 2) are G-protein receptors located on the 
chromosome 17q21. Her2 Neu encodes transmembrane protein 18KD. 
This activates the miogen activated protein kinase pathway and the 
PI3K/AK7 pathway which have a  role in cell proliferation and cell 
differentiation. 
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Human epidermal growth factor includes : 
Her-1 (EGFr) Her-2Neu ( ERBB2), Her-3, Her-4. Of these Her-2 
gene  amplification and protein overexpression occurs  in  tumours such 
as breast malignancy, colorectal carcinoma, gastric carcinoma, 
oesophageal carcinoma & ovarian carcinoma. Nowadays Her-2 neu has 
become an important tumour marker. Anti Her-2  therapy along with 
chemotherapy may improve the survival in Metastatic disease.  
CDX2 : 
(44) 
CDX-2 is Caudal related homeobox-2 protein. This encodes 
transcription factor that is critical for intestinal development in the 
embryonic stage.It is a marker of adenocarcinomas of gastrointestinal 
origin. Can distinguish Colorectal carcinoma extentending into the 
bladder from primary bladder carcinoma and also mucinous 
brochoalveolar carcinoma from metastatic colorectal  carcinoma.  
TAG-72 : 
TAG-72  expression may be enhanced in ulcerative colitis. Its 
expression correlates with the dysplasia –carcinoma sequence 
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CATHEPSIN B: 
Cathepsin B a cystein protease. It has a role in the tumourogenesis 
and invasion of colorectal carcinoma. 
VILLIN :   
Villin is a specialized protein expressed in intestinal mucosa and 
tubular epithelium. Commonly Villin is downregulated in colorectal 
carcinoma, whereas  villin immunoexpression is associated with better 
survival in well differentiated  & small sized tumours. 
HUMAN CHORIONIC GONADOTROPIN: 
Human Chorionic gonadotropin Beta hormone is  produced by 
Human Placenta. In Colorectal adenocarcinomas  increased expression of 
HCG is associated with aggressive behavior of the tumour. 
 PLACENTAL ALKALINE PHOSPHATASE: 
Expression of Placental alkaline phosphatase is found in 23% of 
highly differentiated colorectal carcinomas. 
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WHO HISTOLOGICAL CLASSIFICATION OF TUMOURS OF 
COLON AND RECTUM-EPITHELIAL TUMOURS
(45) 
Adenoma 
 
 Tubular  
 Villous  
 Tubulovillous  
 Dysplasi (Intra epithelial neoplasia, low grade  high grade) 
Serrated Lesions 
 Hyper plastic polyp 
Sessile serrated Adenoma /Polyp 
Traditional serrated Adenoma 
Hamartoma 
 Cowden associated polyp 
Juvenile polyp 
Puetz- Jeghers polyp 
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Carcinoma 
 Adenocarcinoma  
 Mucinous adenocarcinoma  
 Cribriform comedo type adenocarcinoma  
 Medullary carcinoma  
 Micropapi8llary carcinoma 
 Signet-ring cell carcinoma 
 Serrated adenocarcinoma  
Squamous cell carcinoma  
Adenosquamous carcinoma  
Undifferentiated carcinoma  
Spindle cell carcinoma  
Neuroendocrine neoplasms 
Neuroendocrine tumor (NET) 
NET G1 (carcinoid) 
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NET G2 
Neuroendocrine carcinoma (NEC) 
Large cell NEC 
Small cell NEC 
Mixed adenoneuroendocrine carcinoma 
EC cell, serotonin producing NET 
L cell, Glucagon-like peptide producing, and PP / PYY producing NETs 
 Mesenchymal tumors: 
o Leiomyoma 
o Lipoma 
o Angiosarcoma 
o Gastrointestinal stromal tumor 
o Kaposi sarcoma 
o Leiomyosarcoma 
 Lymphomas 
 Secondary tumors 
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ABERRANT FOCI: 
In Colonic carcinogenesis aberrant crypt foci are the earliest 
detectable abnormality. Microscopically, they show thickened epithelium 
and reduced content of mucin.  
There are two main types. 
1. Aberrant crypt foci with features of  hyperplastic polyps. Mutations  in 
RAS proto oncogene  are seen with high frequency. 
2. Dysplastic aberrant crypt foci , are associated with mutations in  APC 
gene. Genesis of Carcinoma in the large intestine is characterized by 
progression of the aberrant crypt foci  through adenoma to carcinoma.  
ADENOMA: 
Adenoma are polypoid growth with areas of epithelial dysplasia. 
Show low to  high grade  dysplasia. Low grade dysplasia show uniform 
elongated nuclei hyperchromatic nuclei, pseudo stratification  and apical 
polarity. Nucleoli inconspicuous and mitosis variable. In high grade 
dysplasia nuclear polarity is lost with vesicular chromatin and prominent 
nucleoli. 
Grossly defined as  
Sessile-without  a stalk. 
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Pedunculated –with a stalk 
Microscopic architecture  divides  the adenomas into 
 Tubular adenomas 
 TubuloVillous adenomas 
 Villous adenomas 
TUBULAR ADENOMA: 
Show closely packed  and branching tubules. Tubules constituting 
more than 80%. They are separated by variable amounts of lamina 
propria. Tubules are considerably regular but may show irregularity with 
budding branching and infolding. 
VILLOUS ADENOMA: 
Villous adenoma contain more than 75% of villi structures. Villi 
consists of  a core lamina propria covered by a sheet of lining epithelium. 
TUBULOVILLOUS ADENOMA: 
Tubulovillous adenoma  contain between 25 to 75% of villous 
epithelium. 
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SERRATEDADENOMA:  
Serrated Adenomas are serrated architectural growths  with 
confluent epithelial  dysplasia characterized by nuclear atypia, nuclear 
stratification and eosinophillic cytoplasm.  
The basal crypts are positive are for Ki67 or proliferating cell 
nuclear antigen. KRAS mutation occurs in advanced stage of serrated 
polyps. 
HYPERPLASTIC POLYP: 
Hyperplastic polyps are sessile pale nodules situated over the 
mucosal folds. Charaterized by elongated  crypts showing  budding or 
little branching  Commonly occur in the sigmoid colon and rectum. The 
proliferating cells lining the crypts show enlarged vesicular nuclei, 
delicate nuclear membrane and prominent nucleoli. KRAS mutation is  
frequent in small hyperplastic polyps arising  in the distal part of the 
bowel  but with no malignant potential. 
JUVENILE POLYPS: 
 Most often occurs in the children and can be sporadic or 
genetically. Juvenile polyps are smooth, spherical with a narrow stalk. 
Microscopically composed of epithelial tubules which may be cystically 
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dilated that are found within the lamina propria. The tubules are 
essentially lined by normal epithelium. Polyps in juvenile polyposis adopt 
marked  infolding .This type of polyps are more prone for dysplastic 
changes and again with increased propensity for malignant change. 
INFLAMMATORY POLYPS: 
Intra luminal projection of the mucosa formed by  non-neoplastic  
mixture of epithelial components and the stromal component. Includes 
Inflammtory pseudopolyps, Prolapse type inflammatory polyps  & 
Inflammtory myoglandular polyps. Histologically  it is  composed of 
inflamed lamina propria and distorted colonic epithelium. 
CHRONIC INFLAMMATORY BOWEL DISEASE
(46) 
10 TO 15% of deaths in inflammatory bowel disease is due to 
colitis associated colorectal carcinomas. Mutations with in the intestinal 
epithelium progresses from colitis to carcinoma transformation 
STAGING : 
     There are many staging systems for  colorectal carcinoma. 
 Duke’s Classification 
 Staging system of  Astler and Collar 
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 Staging system by American Joint Commmittee 
 TNM Classification of staging 
DUKE’S CLASSIFICATION(47) 
          This classification was proposed on 1937.
 
This staging method is 
simplest and is directly related to prognosis. 
 Stage A – only the wall of the bowel is involved by the tumour. 
 Stage B- Tumour extends through the bowel wall. 
 Stage C- Tumours having lymphnode metastases. 
Modifications were proposed and further subclassified stage-C to C1 and 
C2 and also included stage D. 
 Stage C1- Where only regional lymph nodes were involved. 
 Stage C2- Involvement of nodes at mesenteric blood vessels. 
 Stage D  - which indicates distant metastasis. 
Astler and Coller classification
(48) 
This classification was proposed in 1954,
 
 Stage A - Tumour limited to mucosa. 
 Stage B1 - Tumour involves muscularis externa but does not 
     penetrate through it. 
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 Stage B2 - Tumour penetrates through muscularis externa. 
 Stage C1 - Tumour is confined to bowel wall with nodal  
     metastases. 
 Stage C2 - Tumour penetrates through the bowel wall with 
nodal metastases. 
TNM Classification 
(49)
  0 
     This classification has replaced Duke’s Classification. 
 T – Primary Tumour 
 TX  Primary tumour cannot be assessed 
 T0  No evidence of primary tumour 
 Tis  Carcinoma in situ: intraepithelial or invasion of lamina 
propria, but  not through muscularis mucosa into submucosa 
 T1  Tumour invades submucosa 
 T2  Tumour invades muscularis propria 
 T3  Tumour invades through muscularis propria into  the 
pericolorectal   tissues 
 T4a:  Tumor penetrates to the surface of the visceral peritoneum 
 T4b:  Tumor directly invades or is adherent to other organs or 
structures  
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 Regional Lymph Nodes 
 NX  Regional lymph nodes cannot be assessed 
 N0  No regional lymph node metastasis 
 N1: metastasis in 1 - 3 regional lymph nodes 
 N1a: metastasis in one regional lymph node 
 N1b: metastasis in 2 - 3 regional lymph nodes 
 N1c: tumor deposit(s) in the subserosa, mesentery or 
nonperitonealized  pericolic or perirectal tissues without regional 
nodal metastasis 
 N2: metastasis in 4 or more regional lymph nodes 
 N2a: metastasis in 4 - 6 regional lymph nodes 
 N2b: metastasis in 7 or more regional lymph nodes 
 
 Distant Metastasis 
 M0: no distant metastasis 
 M1: distant metastasis 
 M1a: metastasis confined to one organ or site (e.g. liver, lung, 
ovary and nonregional node) 
 M1b: metastases in more than one organ / site or the peritoneum 
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 Stage Grouping: 
Stage 0: Tis   N0 M0  
Stage I: T1-T2 N0 M0 
Stage IIA: T3 N0 M0  
Stage IIB: T4a N0 M0 
Stage IIC: T4b N0 M0 
Stage IIIA: T1-T2 N1/N1c M0 or T1 N2a M0  
Stage IIIB: T3-T4a N1/N1c M0 or T2-T3 N2a M0 or T1-T2 N2b 
M0  
Stage IIIC: T4a N2a M0 or T3-T4a N2b M0 or T4b N1-N2 M0  
Stage IVA: any T, any N, M1a  
Stage IVB: any T, any N, M1b  
SPREAD  AND METASTASIS : 
The tumour spread in either of  the following ways : 
 Direct spread 
 Lymphatic spread 
 Hematogenous spread 
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Direct Spread : 
Tumour extent to the contiguous structures directly by  penetrating 
through the muscularis propria invading into pericolic or perirectal soft 
tissues. Consequences depend upon the anatomic sites involved. 
LYMPHATIC SPREAD : 
Regional lymph nodes are the commonest site of metastatic 
involvement. Lymphatic spread occurs when muscularis mucosae is 
breached and the tumour invades the submucosa. Lymph node 
metastases
(50)
 have great prognostic significance and hence thorough 
search for lymphnodes is mandatory. A minimum number of 14 or 15 
nodes should be recovered from surgical specimens of colorectal 
carcinoma. Pericolonic tumour deposits are isolated tumour nodules. 
These are seen beyond muscularis propria in perineurial, perivascular or 
intravascular location. These must be distinguished from lymph node 
metastasis. 
HEMATOGENEOUS SPREAD: 
Hematogeneous spread occurs through gaining entry into the  
tributaries of portal vein in colon and tributaries of vena cava in rectum.  
Most common sites of metastases are Llver, peritoneum, lung and ovaries 
. 
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Central nervous system, bone, testis, uterus and oral cavity are rare 
sites of secondary metastases. Mucinous and signet ring carcinomas are 
considered as grade III (Poorly differentiated grade).  Medullary 
carcinoma is considered as grade IV (undifferentiated grade). 
TREATMENT: 
Surgical resection is the standard treatment procedure for 
colorectal carcinomas. Depending on the site of tumour is the type of 
surgery.  Ileocolectomy is done for carcinoma of cacum or ascending 
colon. Abdominoperineal resection is done for tumours below peritoneal 
reflection.  Anterior resection is done for tumours in other areas of large 
bowel. For small rectal tumours or those who are unfit for 
abdonimoperineal resection Fulguration, endoscopic transrectal  resection 
and full thickness local excision are done .  
MEDICAL MANAGEMENT :  
Includes  Chemotherapy 
(51)
 and Monoclonal antibody therapy.
(52) 
Radiation Therapy:
((53)  
PROGNOSIS
(2,  54) 
Various clinical and pathologic parameters determine the prognosis of 
colorectal carcinoma  
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AGE : Age has important role in rectal tumours than colonic tumours. 
Both  very young and very old patients have poor prognosis.
 
SEX: Females do better than males. 
CEA SERUM LEVELS : 
Adverse impact on the  prognosis is noted when CEA levels are 
greater than 5ng/ml. 
TUMOUR LOCATION : 
Tumours located in the  proximal  colon do better if they exhibit 
Microsatelite instability , Outcome is poor in tumours located at the  
sigmoid colon and rectum. 
TUMOUR SIZE:  
 Large tumours have poor prognosis. 
TUMOUR EDGE : 
Polypoid tumours have good prognosis  when compared with non-
polyopidal  tumours. 
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TUMOUR MARGIN AND INFLAMMATORY REACTION : 
Tumours with pushing margins have favourable prognosis. 
Tumours infiltrated by Inflammatory infiltrate at the interphase between 
tumour and nearby tissue have a better prognosis. 
LOCAL EXTENT : 
Tumours restricted to mucosa and submucosa have good 
prognosis.. 
VASCULAR INVASION : 
Vascular invasion involving the extramural blood vessels is of 
more prognostic significance than  the involvement of  the vessels within 
the bowel wall. Vascular invasion is associated with poor prognosis. 
PERINEURIAL INVASION : 
This denotes  advanced stage and has worst prognosis. 
PERICOLONIC TUMOUR DEPOSITS : 
Presence of  pericolonic  tumour deposits have worse  prognosis. 
SURGICAL MARGIN : 
Radial margin involvement in rectal carcinoma indicates poor 
prognosis. Local recurences are common. 
62 
 
MICROSCOPIC TYPE AND PATTERN: 
Medullary carcinoma has a favourable prognosis whereas 
Mucinous, signet ring and anaplastic carcinomas have poor prognosis.  
GENETIC FACTORS : 
Expression and related antigens such as sialyl-TN, sialyl-Lewis 
(x),
(55)
 expression of fascin, PR6 and p16INK4 are associated with bad 
prognosis. Tumours with allelic loss of chromosome 18q  and loss of 
claudin-1 have poor prognosis. Tumours with HLA-DR expression, Bcl-2 
protein expression  and TGF-beta1 mutations have good prognosis. 
Microsatelite instability
(56)
 status do determine the prognosis in the 
colonic cancers. 
LYMPH NODE INVOLVEMENT : 
Lymph node involvement reduces the  survival rate. Involvement 
of  nodes away from the  tumour indicates poor prognosis. The more 
number of nodes involved the worse is the prognosis. 
LYMPH NODE REACTION :
(57)
  
Reactive changes produced by cell-mediated immune  response 
indicate a good prognosis. 
 
STAGING AND GRADING 
(58)
  
Staging and grading have implications on the prognosis. 
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OBSERVATION AND RESULTS 
            The present study is a prospective study conducted in the 
Department of Pathology, Coimbatore Medical College Hospital. A total 
of 36 cases of colorectal specimens  that were  received over the period of 
July 2016 t o June 2017,  were studied  
          Ethical clearance was obtained from Ethics committee of  
Coimbatore Medical College Hospital, Coimbatore. 
          Histopathology of  colorectal carcinoma  was studied  and 
expression  of  Kras and p53 in colorectal carcinoma  was undertaken in 
36 cases .The results were analysed  and compared with related 
previously done studies. 
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OBSERVATION & RESULTS 
Table 1: Mean age of the study 
 
 
N Minimum Maximum Mean 
Standard 
Deviation(SD) 
AGE 36 33 80 55.11 13.02 
 
Table 2: Age distribution  
Age distribution Frequency Percent (%) 
<40 9 25.0 
41-50 3 8.3 
51-60 10 27.8 
61-70 12 33.3 
>70 2 5.6 
Total 36 100.0 
 
 
In the  present study  distribution of colorectal carcinoma is  high  
in the  age  group  of    61-70, followed by the age group 51-60,and < 40 
group. Distribution is low in the age groups   41-50  and in the individuals 
above 70years. 
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Table 3: Gender distribution  
Gender distribution Frequency Percent (%) 
Male 26 72.2 
Female 10 27.8 
Total 36 100.0 
 
 
 The present study show that colorectal carcinoma is more common 
in men than  in women.  
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Table : 3 
ADENOCARCINOMA USUAL TYPE –GROSS FEATURES: 
POLYPOID   GROWTH                       3 
ULCERATIVE  GROWTH      6 
INFILTRATIVE  GROWTH      6 
ULCERO INFILTRATIVE  GROWTH    7 
ULCEROPROLIFERTIVE  GROWTH    12 
CENTRAL ULCERATION      1 
EDGES WELL DEMARCATED     3 
INFILTRATING INTO ADJACENT PERICOLC TISSUES   6 
 
 
The above picture chart  shows the gross  features of colorectal 
adenocarcinoma The commonest Feature  noticed  is the 
lceroproliferative  type of  growths  followed by ulceroinfiltrative 
,infiltrative and  the ulcerative  growths. 
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Table : 4 
COLORECTAL CARCINOMA  – HISTOPATHOLOGICAL 
FEATURES. 
HISTOPATHOLGICAL FEATURES PRESENT ABSENT 
PRESENCE OF EXTRACELLULAR 
MUCIN 
6 30 
TUMOUR CELL PLEOMORPHISM 14 22 
SURROUNDINGINFLAMMATORY 
REACTION  
3 36 
PAPPILARY CONFIGURATION  1 35 
VILLOUS CONFIGURATION  6 30 
MUSCULAR INVASION  22 14 
 INVASIONINTO PERICOLIC PAD OF 
FAT  
16 20 
INVASION INTO PERINEURAL 
SPACE 
4 32 
LYMPHOVASCULAR INVASION 5 31 
  
 
The above picture chart  of  histopathological features of colorectal 
carcinoma show invasion of the carcinoma into the vascular structures 
and  perineural spaces in five and four cases respectively. Surrounding 
inflammatory reaction noticed in  three cases. 
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Table 5: HPE DIAGONSIS 
HPE DIAGONSIS Frequency Percent (%) 
Adenocarcinoma Well 
Differentiated 
8 22.2 
Moderately Differentiated 
Adenocarcinoma 
10 27.8 
Mucinous 
Adenocarcinoma 
6 16.7 
Poorly Differentiated 
Adenocarcinoma 
12 33.3 
Total 36 100.0 
 
 
 
The  above chart shows that porly colorectal adenocarcinoma  is the 
commonest colorectal carcinoma  followed bymoderately differentiated 
adeno carcinoma well differentiated adeno carcinoma. In this study 
poorly differentiated carcinoma edges the moderately and well 
differentiated carcinomas. 
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Table 6: TYPES OF COLORECTAL CARCINOMA. 
HPE Frequency Percent (%) 
MUCINOUS 6 16.7 
ADENOCARCINOMA 30 83.3 
Total 36 100.0 
 
 
The above bar diagram depicts that Adenocarcinoma is the 
common type  followed by Mucinous carcinoma.  
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Table 7: GRADING OF ADENOCARCINOMA USUAL TYPE 
GRADE Frequency  Percent (%) 
WELL 
DIFFERENTIATED 
8 26.7 
MODERATLEY 
DIFFERENTIATED 
10 33.3 
POOR 
DIFFERENTIATED 
12 40.0 
Total 36 100.0 
 
 
 
The present study show that the distribution of poorly 
differentiated Carcinoma  is 40%  and  is marginally higher than the 
moderately differentiated carcinoma (33.3%) The well differentiated 
carcinoma shows a distribution of about 26.7%. 
 
 
 
0
2
4
6
8
10
12
Well 
Differentiated
Moderately 
Differentiated
Poorly 
Differentiated
8
10
12
GRADE
71 
 
Table 8: ASSOCIATION OF AGE WITH HPE DIAGNOSIS 
Age Group 
Well 
differentiated 
adenocarcinoma 
Moderately 
differentiated 
adenocarcinoma 
Poorly 
differentiated 
adenocarcinoma 
<40 3(42.9%) 2(28.6%) 2(28.6%) 
41-50 0(0.0%) 0(0.0%) 3(100.0%) 
51-60 1(14.3%) 4(57.1%) 2(28.6%) 
61-70 4(33.3%) 4(33.3%) 4(33.3%) 
>70 0(0.0%) 0(0.0%) 1(100.0%) 
 
 
The present study show that 1/3
rd
 of the colorectal carcinoma is 
comprised by the age group 61-70 years and among them all the grades 
are evenly distributed. In the individuals less than 40years well 
differentiated carcinoma is more common than the other two grades. In 
the age group51-60 moderately differentiated is high whereas in the age 
group 41-50 poorly differentiated is high. 
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Table 9: ASSOCIATION OF GENDER WITH HPE DIAGNOSIS 
 
 
Well 
differentiated 
adenocarcinoma 
Moderately 
differentiated 
adenocarcinoma 
Poorly 
differentiated 
adenocarcinoma 
MALE 5(33.3%) 8(38.1%) 8(38.1%) 
FEMALE 3(33.3%) 2(22.2%) 4(44.4%) 
 
 
 
The distribution of poorly differentiated and moderately 
differentiated carcinomas are equally distributed in men with well 
differentiated comprising a little less. In the case of women poorly 
differentiated carcinoma is high followed by well differentiated and the 
moderately differentiated carcinomas. 
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Table 10: ASSOCIATION OF HPE DIAGNOSIS WITH KRAS 
HPE DIAGNOSIS 
KRAS 
POSITIVE NEGATIVE 
Well differentiated 
Adenocarcinoma 
5(62.5%) 2(25.0%) 
Moderately 
differentiated 
adenocarcinoma  
5(50.0%) 5(50.0%) 
Poorly differentiated 
adenocarcinoma 
4(33.3%) 8(66.7%) 
 
 
 
From the above it is inferred that Kras expression  is high in well 
differentiated followed by moderately differentiated and poorly 
differentiated carcinomas. 
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Table 11: ASSOCIATION OF HPE DIAGNOSIS WITH P53 
HPE DIAGNOSIS 
 
P53 
POSITIVE NEGATIVE 
Well differentiated  
Adenocarcinoma 
6(75.0%) 2(25.0%) 
Moderately differentiated 
adenocarcinoma  
5(50.0%) 5(50.0%) 
Poorly differentiated 
adenocarcinoma 
5(41.7%) 7(58.3%) 
 
 
 
The study on colorectal carcinoma show that p53 expression is 
high in the case of well differentiated carcinomas – 75% followed by 
moderately differentiated with 50%and poorly differentiated carcinomas 
showing about 41.7%.This indicates that the expression of P53 
decreases with the advancement of  colorectal  carcinoma. 
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Table 12:  AGE WITH HPE DIAGNOSIS IN MUCINOUS 
ADENOCARCINOMA 
AGE Mucinous Adenocarcinoma 
<40 2(100.0%) 
51-60 3(100.0%) 
>70 1(100.0%) 
 
 
 
 
The above bar diagram show that mucinous carcinoma is more 
common the age group of 51-60 years. 
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Table 13:  GENDER WITH HPE DIAGNOSIS IN MUCINOUS        
ADENOCARCINOMA 
 
GENDER Mucinous Adenocarcinoma 
MALE 5(100.0%) 
FEMALE 1(100.0%) 
 
 
 
 
The above bar chart show that mucinous carcinoma is fairly 
common in  men  
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Table 14: ASSOCIATION OF HPE DIAGNOSIS WITH KRAS IN 
MUCINOUS ADENOCARCINOMA 
 
 
KRAS 
NEGATIVE 
Mucinous Adenocarcinoma 6(100.0%) 
 
Table 15: ASSOCIATION OF HPE DIAGNOSIS WITH P53 IN MUCINOUS 
ADENOCARCINOMA 
 
 
P53 
POSITIVE NEGATIVE 
MUCINOUS 
ADENOCARCINOMA 
2(33.3%) 4(66.7%) 
 
 
The above data give the fact that P53 expression is low and  
KRAS expression is insignificant in Colorectal Mucinous carcinoma   
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Table 16: ASSOCIATION OF KRAS WITH P53  
 
 
KRAS 
P53   
P VALUE POSITIVE  NEGATIVE  
POSITIVE 11(78.6%) 3(21.4%) 
 
.006* NEGATIVE 7(31.8%) 15(68.2%) 
*-STATISTICALLY SIGNIFICANT (P<0.05) 
 
 
 
11- 78.6% cases of colorectal carcinoma included in our study 
show both p53 and Kras positivity. This relation ship is found to be  
statistically significant. 
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MATERIALS AND METHODS 
STUDY DESIGN              :   Prospective study.  
PLACE OF STUDY          :  Department of Pathology,  
  Coimbatore Medical college, 
  Coimbatore.                                                     
STUDY PERIOD                : July 2016– July 2017 
INCLUSION CRITERIA         : Patients detected with colorectal   
carcinoma, Patients undergoing 
resection surgery Patients with out 
chemotherapy Both genders.                                                              
Resected colorectal surgical 
specimens. Adequately fixed 
specimens. 
EXCLUSION CRITERIA    :  Inadequately fixed specimens.           
On Radiation therapy and 
Chemotherapy. 
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Sections of  four micron  thickness  cut on to uncoated and coated slides .  
The sections placed on coated slides are  incubated  at 58 degrees 
overnight. The uncoated slides stained  with hematoxylin and eosin stain.  
METHOD OF HEMATOXYLIN AND EOSIN STAINING : 
REAGENTS USED:  
1. Erhlich’s Hematoxylin solution  
2. 1% Eosin Y solution  
3. 1% Acid alcohol solution  
PROCEDURE  
Sections are deparaffinized in xylene by immersing the specimens for 30 
seconds.  
Sections are then placed in Isopropyl alcohol for 15 minutes. 
Washed  in running tap water. 
Stained with Erhlich’s   Haematoxylin solution  for 15 minutes. 
Washed  in running tap water. 
Differentiated with acid alcohol  1% solution 
 Allowed for Blueing for about 10 minutes. 
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Counterstained  with eosin 1 % solution – 3 to 4 dips. 
Washed in tap water. 
Sections are air-dried.  
Sections are mounted with DPX. 
Haematoxylin and eosin stained specimens are studied . 
Pathological diagnosis is made on the Histopathological  features. 
IMMUNOHISTOCHEMISTRY : 
METHOD : 
Two Step indirect technique.  
PRINCIPLES OF IMMUNOHISTOCHMISTRY : 
The principle of  IHC technique is  detection of antigens expressed  by 
the cells in the tissues. Done in two step method. 
Primary antibody (ie KRAS & P53) using specific epitopes is bound to 
the  antigens.  
The antigen-antibody binding is then detected by calorimetric reaction.  
REAGENTS : 
Peroxide Block : 3% hydrogen peroxide in water.  
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Power block:  contains casein and properity additives with 15mM sodium 
azide in PBS. It is a protein blocking reagent and it is  highly effective.  
Chromogen : DAB-33’ diaminobenzidine.  
Liquid DAB substrate : Tris buffer which contains peroxides and 
stabilizers.  
Super enhancer reagent. 
Counterstain  with Meyer’s  Hematoxylin.  
Buffer solutions 
CITRATE BUFFER  (pH 6.0) 
Trisodium Citrate   : 2.94 grams 
Distilled water  : 1000 ml 
IN HCL   : 5 ml 
TRIS EDTA : (pH 9.0)  
TRIS buffer salt          : 6.05 grams 
Disodium EDTA        : 0.744 grams 
Distilled water            : 1000ml 
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TRIS BUFFER(pH 7.6) 
TRIS buffer salt         : 0.605 grams 
Sodium Chloride        : 8 GRAMS 
Distilled water  : 1000 ml 
 IN HCL   : 3 ml 
PROCEDURE : 
Sections are deparaffinized with xylene – 3 changes each 10 minutes. 
Absolute alcohol for 5 minutes with two changes , 90% alcohol -5 
minutes. 
Washed  in running tap water f- 10 minutes 
Running water-5 Minutes. 
Pre heat – Ag retrieval buffer 600degree –c  3 Minutes. 
Distilled water -2 Minutes. 
Antigen retrieval: 
450degree –C- 5 Minutes. 
450degree –C- 5 Minutes. 
800 degree –C- 5 Minutes 
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800 degree –C- 5 Minutes 
800 degree –C- 5 Minutes 
Sections are Cooled to room temperature  
Distilled water -5 Minutes 
TBS buffer wash - 5 minutes with 2 changes 
Peroxide block for 10 minutes 
TBS buffer wash -5 minutes with 2 changes 
The sections are covered with primary antibody – 1hour 
Washed with buffer-taken out immediately 
Washed with TBS buffer - 5 minutes with 2 changes 
Secondary Antibody(HRP Label)-30-minutes. 
Rinsed in buffer. 
Washed with TBS buffer – 5  minutes 2 changes  
DAB Chromogen and substrate buffer -5 to 7 minutes.   
Rinsed in distilled water.  
Counterstained with Hematoxylin-Dipped 
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 Washed with tap water - 5 minutes 
Air dried  and mounted  in DPX 
IMMUNOHITOCHEMICAL EVALUATION: 
Sections examined under high power objective for positive 
immunoreactivity. 
Positivity is considered when the neoplastic cells have cytoplasmic, 
(KRAS) staining 
Nuclear  golden  brown  staining( P53) .  
Semiquantitative scoring carried out.  
P53:
(59) 
 Nuclear staining.  
None (<5%), 
Weak positivity (1+, 5%  - 25%), 
Moderate positivity  (2-,++, 25% -75%) , 
Intense Positivity   (3,+++, > 75%) 
Nuclei staining  5% and above  considered positive . 
K-RAS:   Cytoplasmic staining.
(60) 
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Majority of the cells positive-more than   -  75%- 3+ 
Moderately stained  positive                     - 25-50%   2+  
Focal positive                                           -  Less than 25%   1+   
3+ & 2+ stains are considered expression of  K-Ras protein 
DATA: 
Tumours were subtyped using H & E sections according to the WHO 
classification. Taking into account the Patient age, gender KRAS & P53 
status were determined and expressed  accordingly. 
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DISCUSSION 
       Colorectal carcinoma though common worldwide has a low 
incidence in India. It has a significant geographical variation in the 
incidence and the clinical presentation also varies. In the present study  of 
Kras and P53 expression  in colorectal carcinoma a  total of 36 cases were 
studied . Among them 26 were men constituting 72.2%  with women 
numbering 10 and constituting 27.8%. In their study on colorectal  
carcinoma Patil P.S.et-al
(61)
 Indian Jsurg oncol 2017men comprised of 
520 cases  constituting 65%and women comprised of 280 cases 
constituting 35%. Both of the  studies are comparable showing marginal 
differences. The mean age in the present  study is 55.11 years whereas 
mean age in the above quoted study is 47.2years. 
In the present study distribution of colorectal carcinoma is high in 
age group 61-70 years 12 cases- 33.3% , followed by the age group 51-60 
years  10 cases , 27.8% and in the   group <40- 9  cases 25% . Pramila 
kumari et-al
(62)
  in their  study  on age wise incidence in colorectal 
carcinoma  found that the age group 41-50 comprising 296 cases out of 
1096 cases constituting 27%,   age group 51-60  comprisig 262 cases  
constituting 23.9% and age group < 40 comprising 246 cases  constituting 
24.34%. Though the present study and the quoted study have  differences 
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in the corresponding age groups  both studies show similar number of  
cases occurring in the age group <40 years .  
Gupta et-al
(63)
 in their study  have  emphasized the increasing trend 
of colorectal carcinoma in the age group <40yrs.  The present study on 
colorectal carcinoma show adenocarcinoma   comprising  30 cases out of 
a total of 36 constituting 83.3% and mucinous colorectal carcinoma 
comprising 6cases constituting 16.7%.As per WHO  adenocarcinoma 
constitute 85-90%of all colorectal carcinomas and mucinous  carcinoma 
constituting 8-10%.Though mucinous carcinoma is high in the present  
study ,the number of  adenocarcinoma studied is comparable with the 
WHO  
              In the present study on colorectal carcinoma according to 
grading well  differentiated  carcinoma comprise of 8 cases constituting 
26.7%,moderately  differentiated comprising 10 cases constituting 33.3% 
and poorly differentiated  comprising 12 cases constituting 40%. Tapas 
et-al
(64)
 in their study on colorectal  carcinoma have found that out of 
56.8% of colorectal carcinoma poorly  differentiated constituting 29% 
moderately differentiated constituting 18.3% and well differentiated 
constituting 9.5%. In both of the present and the quoted  studies the 
majority  among the graded colorectal carcinomas happen to be  poorly 
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differentiated followed by moderately and the well differentiated 
colorectal  carcinomas. 
In the present study on colorectal carcinoma grossly 
ulceroprolifertive growths are more common comprising 12cases 
constituting 40% followed by ulceroinfiltrative growths comprising  
7cases constituting 23.3% and ulcerative  growths comprising 6 cases and 
constituting 20%.. 
       Histopathologically lymphovascular invasion was noticed in five 
cases and  perineural invasion in four cases.  Inflammatory reaction with 
lymphocytic  infiltration was noticed in three cases.  In the present study 
papillary configuration was noticed in one case and villous configuration 
was identified in 6 cases constituting 20%.  According to the present 
study Kras expression was obsereved in 12cases costituting 46,7% The  
present study show that  5 cases of moderately differentiated  constituting  
50% expressed Kras protein and 4cases of poorly differentiated colorectal  
carcinoma constituting 33.3%  expressed  Kras. Mahmoud et-al
(60)
 in their 
study have observed that 42.3 cases expressed Kras protein Moderately 
differentiated grades expressed Kras protein in 50%of cases and poorly 
differentiated graded colorectal carcinomas expressed in 38.9% of cases. 
Although  Kras expression was similar in both studies poorly 
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differentiated graded carcinomas showed  little  show difference and the 
inference is that as the grade increases Kras expressiondiminished.  
Reports from various studies show that p53 expresion in colorectal 
carcinoma range from 52 -61 %.The present study show that  16 cases 
constituting  53.3% of colorectal carcinoma  expressed p53 protein .75% 
of  well differentiated , 50% of moderately  differentiated and 41.7% of 
poorly differentiated expressed p53. Peter F Rambau et-al
(35)
   in   their 
study found that 56% of colorectal carcinoma expressed p53 protein.  
They have also observed that 65.9% well differentiated grades  54.3% of 
moderately grades and 45.5% of poorly differentiated carcinomas 
expressed p53. From their study they have made an observation that there 
is a decrease in the expression of p53 with worsening of  colorectal 
carcinoma histological grade.    
      Kras among all human Ras isoforms is the most often mutated in all 
cancers and mutated in about 30-40% of colorectal cancers. According to 
Amanda et-al development of  Kras mutation is important in the multistep 
process of colorectal carcinogenesis.  Pathologist expertise is mandatory 
for quality kras testing and there by determining the treatment of 
colorectal carcinoma. Pathologist play a role in the identification of 
suitable sample for analysis and provide consultations with surgeons and 
oncologists.  Pylayeva –gupta et(66)-al have studied and described how the 
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Ras genes abuse the signaling pathways thereby interrupting the 
multicellular processes and drive tumorogenesis.   
Study by Akshatha et-al
(67)
 have emphasized that p53 protein has a 
major role in the development of colorectal carcinoma, over expression is 
relatively high, in number of cases of colorectal carcinomas.  Farina 
sarsqueta  et-al
(68)
 have observed that impaired p53 protein is detrimental 
on the survival of colorectal carcinoma. The study of Nicolas piton et-
al
(69)
 represent that immune  histochemistry  may facilitate the screening 
of mutated colorectal cancer patients for administration of Epidermal  
growth  factor receptor inhibitors therapy  and Chemotherapy. 
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SUMMARY 
The study titled as ―Expression of p53 and Kras with  
immunohistochemical markers in colorectal carcinoma in a tertiary  care 
centre‖ was conducted in Coimbatore Medical College, Coimbatore 
Medical College, Coimbatore during the period 2016-2017.  
         The Study consists of 36 cases of Colorectal carcinoma which 
includes 30 cases of colorectal Adenocarcinoma and 6 cases of mucinous 
colorectal carcinoma. All the cases were subjected to 
immunohistochemistry using Kras and P53 markers. Individuals who 
have undergone irradiation and chemotherapy were excluded from the 
study. Statistical analysis was done and the results were compared with 
the related previously undertaken studies. 
A total of 36 cases were studied , colorectal adenocarcinoma 
comprising 30 cases (83.3%) and  mucinous  adenocarcinoma   was only 
6 cases  16.7% 
         The present study shows  that colorectal adenocarcinoma commonly 
occurs after the age of 50. It is more common among the age group 61-
70.years. The study also shows that the occurrence of colorectal 
carcinoma in individuals below 40 year is on increasing trend . The mean 
age of colorectal carcinoma in the present study is  55.11 yrs.  
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               The study show that colorectal adenocarcinoma is more common 
in men   than in women.  
The study also show that poorly differentiated colorectal 
adenocarcinoma comprising 12 cases out of 30 constituting 40% followed 
by moderately differentiated colorectal carcinoma with 10 cases(33.3%) 
and well differentiated colorectal carcinomas  comprising  8 cases and 
constituting  26.7%.. 
14 out of 30(46.70%) colorectal adenocarcinomas expressed Kras 
protein. 16 out of 30 (53.33%) colorectal adenocarcinomas expressed P53 
protein.  
Thus well differentiared colorectal adenocarcinoma   show high 
expression of  p53 and  Kras . As the grade of colorectal adenocarcinoma 
worsens the expression of  p53 and Kras  decreases.We indirectly by 
immunohistochemical study observe that in our setup colorectal 
adenocarcinoma are constituted mostly of CpG island Hypermethylation 
type without microsatellite instability which will help the oncologist to 
asses the prognosis and choose the mode of treatment. Further studies 
could be  pursued  with  larger sample  size  to critically analyze  the 
above findings. 
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CONCLUSION 
Kras  and  P53 mutations  are  common  in  colorectal  carcinomas .    
Oncogene Kras mutation is important in the process of colorectal 
carcinogenesis. Kras  expression is noted in 46.7% of cases in the present 
study. Kras mutation confers resistance to epidermal growth factor 
receptor inhibitors during patients treatment. Kras mutation in colorectal 
carcinoma is associated with  poor survival of the patients along 
aggressive behaviour of the tumour.  
           Tumour supressor gene P53 mutation plays a crucial role in the 
development of colorectal carcinoma. P53 mutations shed their tumour 
suppressive functions and promote tumorogenesis. P53 mutation is 
detrimental for the survival colorectal carcinoma patients. Many of the 
colorectal cases show both mutations. 
           Kras amplification as well as  Kras mutations are associated with 
poor  response to Epidermal growth factor receptor inhibitors like 
cetuximab and panitusumab. P53 mutations in colorectal adenocarcinoma 
render the chemotherapeutic agents  especially  5 fluouracil  ineffective. 
          Identification of Kras expression and P53 expression will help in 
redefining the targeted therapy with monoclonal antibodies and 
chemotherapy. Hence identification of  kras expression and p53  in 
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colorectal carcinoma using Immunohistochemistry  an economical and 
less time consuming procedure may be more beneficial for the colorectal 
carcinoma patients.  
           Routine use of p53 and Kras would help  to choose   individualized 
option treatment  n colorectal carcnoma patients.Hence chemotherapy 
and  monoclonal antibobdies  therapy regimen shall be based on p53 and 
Kras mutation status  to effectively treat the patients with colorectal 
carcinoma.   
        Further study with larger sample size will help to reconfirm our 
findings. 
 
 
 
 
 
ANNEXURE 
ANNEXURE 1 
PROFORMA 
Coimbatore medical college 
Department of   Pathology 
Coimbatore 
Particulars of the patient: 
Name  :                                                          Age: 
Ward    :                                                       IP. No : 
Address:                                                       Occupation: 
 
 Presenting complaints: 
 Pain lower abdomen, abdominal discomfort. 
 Bowel habits 
Loss of  appetite and weight   
Bleeding per rectum  
Tiredness and fatigability 
Constipation,  
Past history: 
History of  radiation or chemotherapy. 
History of previous surgeries. 
 Family history 
Personal history: 
Diet: 
Smoking: 
General examination:              
Nourishment :                    Built:                                              Conscious:        
Pallor:                                Jaundice:                                         Clubbing: 
Lymphadenopathy :          Edema: 
Vitals: 
Pulse rate:                     BP:                RR:        
Examination of the abdomen: 
Clinical diagnosis: 
Investigations: 
USG :       Abdomen 
CT/MRI: Abdomen 
Microscopic findings: 
Histopathological diagnosis 
Immunohistochemistry: 
FINAL DIAGNOSIS 
Annexure-II 
S. 
NO 
AGE SEX  
HOSPITAL 
NO 
HPE 
NO 
CLINICAL 
DIAGONIS  
HPE 
DIAGONIS 
KRAS-
EXPRESSION 
1+ -(Focal 
positivity) 
Negative 
2+-(Moderate 
staining)Positive3+ 
- (Majority cells 
staining) Positive 
P53-
EXPRESSION 
<5% -Negative 
5-25% 
1+positive          
25 - 75%          
2+ Positive        
>75%                       
3+ Positive 
1 51 M 86327 91/16 
Growth - 
Sigmoid colon 
Moderately 
differentiated 
Adenocarcinoma 1+Negative < 5 % Negative 
2 63 F 8118 552/16 
Carcinoma 
Rectum 
Adenocarcinoma 
Well 
Differentiated 1+Negative < 5 Negative 
3 65 M 16656 826/16 
carcinoma 
Ascending colon 
Moderately 
differentiated 
Adenocarcinima 2 +positive 
5  - 25 % 
Positive 
4 65 M 70842 897/16 
Carcinoma 
Descending colon 
Adenocarcinoma 
welldifferentiated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Negative < 5 % Negative 
5 33 M 25674 1414/16 
carcinoma 
Ascending colon 
Mucinous 
Adenocarcinom Negative 
5 - 25 % 
Positive  
6 58 F 43390 2210/16 
Carcinoma 
Caecum 
Moderately 
differentiated 
Adenocarcinoma 1 + Negative  < 5 % Negative  
7 40 M 23160 1468/16 
Growth-
Rectosigmoid 
Poorly 
Differeentiated 
Adenocarcinoma 1 + Negative < 5 % Negative 
8 54 F 42026 2178/16 Growth Rectum 
Adenocarcinoma 
Well 
Differentiated 2 + Positive 
25 - 75 % 
Positive 
9 68 m 58036 3098/16 
Growth -Right 
colon /caecum 
Moderately 
Differentiated 
Adenocarcinoma 1 + Negative < 5% Negative 
10 40 M 65308 3696/16 
Growth -
Transverse colon 
Adenocarcinoma 
Well 
Differentiated 3 + positive > 75 % Positive 
11 65 M 70508 4020/16 
carcinoma 
Rectum 
Modertely 
differentiated 
Adenocarcinoma 1 + Negative  < 5 % Negative 
12 45 F 76288 4237/16 
Carcinoma Right 
colon 
Poorly 
Differeentiated 
Adenocarcinoma 1 + Negative 
5 - 25 % 
Positive  
13 68 M 80014 4352/16 Growth-Rectum 
Adenocarcinoma 
Well 
Differentiated 2 + Positive 
5 - 25 % 
Positive  
14 33 M 34665 1961/16 
Growth 
Ascending colon 
Adenocarcinoma 
Well 
Differentiated 3 + Positive 
25 - & 75 % 
Positive 
15 48 F 846231 90/17 
Carcinoma-
Rectum 
Poorly 
Differeentiated 
Adenocarcinoma 2 + Positive 
25-75% 
positive 
16 65 M 2645 166/17 Growth Rectum 
Adenocarcinoma 
Well 
Differentiated 2 + Positive` 
25 - 75 % 
Positive  
17 45 M 82171 208/17 Carcinoma colon 
Poorly 
Differeentiated 
Adenocarcinoma 1 + Negative <  5 %Negative  
18 70 F 82171 668/17 
Rectosigmoid 
Growth 
Poorly 
Differeentiated 
Adenocarcinoma 2 + Positive  
25 - 75 % 
Positive 
19 51 M 7563 773/17 
Rectosigmoid 
Growth 
Moderately 
differentiated 
Adenocarcinoma 2 + Positive. 
25 - & 75 % 
Positive  
20 59 M 23933 1531/17 
Carcinoma 
colon/Descending 
colon Sigmoid 
colon junction 
Poorly 
Differeentiated 
Adenocarcinoma 1 +  Negative < 5 % Negative  
21 70 M 24659 1319/17 
Rectosigmoid 
Growth 
Poorly 
Differeentiated 
Adenocarcinoma 3 + Positive  
25 - 75 % 
Positive  
22 55 M 30043 1614/17 
Carcinoma 
Caecum 
Mucinous 
Adenocarcinom Negative 
5 - 25 % 
Positive  
23 36 F 21416 1653/17 
Sigmoid colon 
Growth 
Adenocarcinoma 
Well 
Differentiated 1 + Negative 
5 - 25 % 
Positive  
24 35 M 29622 1695/17 Sigmoid Growth 
Mucinous 
Adenocarcinom 1 + Negative  
<  5 % 
Negative  
25 65 M 40048 2172/17 
Growth 
Ascending colon 
Poorly 
Differeentiated 
Adenocarcinoma 1 + Negative < 5 % Negative  
26 54 M 109811 2440/17 Growth Rectum 
Moderately 
Differentiated 
Adenocarcinoma 1 + Negative  < 5 % Negative  
27 65 M 110814 2441/17 
Growth 
Descending 
Colon 
Poorly 
Differeentiated 
Adenocarcinoma 1 + Negative  < 5 % Negative  
28 57 M 43188 2372/17 Growth Caecum 
Mucinous 
Adenocarcinom 1 + Negative  < 5 % Negative  
29 67 F 45737 2392/17 Sigmoid Growth 
Moderately 
differentiated 
carcinoma 3 + Positive > 75 % Positive  
30 40 F 30478 1706/17 
Carcinoma Right 
colon 
Poorly 
Differeentiated 
Adenocarcinoma 1 + Negative  < 5 % Negative  
31 80 M 82297 2713/17 Growth Caecum 
Poorly 
Differeentiated 
Adenocarcinoma 1 + Negative  < 5 % Negative  
32 60 M 79342 2675/17 
Carcinoma 
Rectum 
Poorly 
Differeentiated 
Adenocarcinoma 2 + Positive 
25 - 75 % 
Positive  
33 56 F 57512 2720/17 
Growth 
RectoSigmoid 
Junction 
Mucinous 
Adenocarcinom  Negative  < 5 % Negative  
34 78 M 80190 2584/17 
Recto Sigmoid 
Growth 
Mucinous 
Adenocarcinom  Negative  < 5 % Negative  
35 40 M 24572 1287/17 
Recto Sigmoid 
Growth 
Moderately 
differentiated 
carcinoma 2 + Positive 
25 - 75 % 
Positive  
36 40 M 65308 
3076 
/17 
carcinoma 
Rectum 
Moderately 
Differentiated 
Adenocarcioma 2 + Positive 5-25% Positive 
 
ANNEXURE III- LIST OF ABBREVIATIONS 
TP53               :     Tumour protein 
Kras                :     Kirsten rat sarcoma 
MAPK            :     Mitogen activated protein kinase 
PI3K               :     Phosphoinositidyl  3—Kinase 
GDP                :    Guanosine diphophate 
EGFR              :    Epidermal growth factor receptor 
NSAID            :    Nonsteroidal anti-inflammatory drug 
APC                :     Adenomatous poliposis coli  
FAP                :     Familial  Adenomatous poliposis 
TCF               :    T cell factor 
CEA               :     Carcinoembryonic antigen   
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